Weekly Digest – December 2024 Weekly Digest – December 2024 04 Dec 2024: Henlius receives IND approval from NMPA for a phase 1b/2 clinical trial of its novel PD-L1-targeting ADC HLX43 Shanghai Henlius Biotech’s HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), […]
Weekly Digest – December 2024 Weekly Digest – December 2024 03 Dec 204: FDA grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the treatment of certain patients with previously treated advanced or metastatic nonsquamous non-small cell lung cancer with […]
Weekly Digest – December 2024 Weekly Digest – December 2024 04 Dec 2024: GSK goes East again, snagging option on preclinical DualityBio ADC for $30M GSK has entered into a deal with Duality Biologics to license a preclinical antibody-drug conjugate […]
Weekly Digest – December 2024 Weekly Digest – December 2024 04 Dec 2024: GSK goes East again, snagging option on preclinical DualityBio ADC for $30M GSK has entered into a deal with Duality Biologics to license a preclinical antibody-drug conjugate […]
Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: Adcendo raises $135m as ADC funding frenzy continues Adcendo raised $135 million in funding to advance its portfolio of first-in-class ADCs into clinical trials Company’s ADC candidate, […]
